NCT02109744View on ClinicalTrials.gov

Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 1, 2022

Study Completion Date

January 1, 2022

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

Decitabine

Trial Locations (1)

14642

University of Rochester, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT02109744 - Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients | Biotech Hunter | Biotech Hunter